Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The document serves as a notification of transactions involving Persons Discharging Managerial Responsibility (PDMRs) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific share transaction:
- Share Sale Price: £14.15 per share.
- Transaction Date: February 17, 2012.
- Purpose: To meet tax liabilities following the vesting of awards granted in 2009 under the GlaxoSmithKline Share Value Plan.
Material Changes
The filing details changes in shareholdings for two PDMRs:
- Mr. P. Thomson: Sold 900 shares; retained 830 shares.
- Mrs. V. Whyte: Sold 900 shares; retained 830 shares.
No other material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the total number of shares held by Mr. P. Thomson and Mrs. V. Whyte post-transaction.
- Confirm the tax implications of the 2009 Share Value Plan vesting.
- Review the company's Form 20-F for comprehensive financial performance data, as this 6-K does not contain it.